Ramm Pharma Corp Stock Fundamentals
Fundamental analysis of RAMM Pharma allows traders to better anticipate movements in RAMM Pharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
RAMM |
RAMM Pharma Corp Company Return On Equity Analysis
RAMM Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current RAMM Pharma Return On Equity | -0.12 |
Most of RAMM Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RAMM Pharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, RAMM Pharma Corp has a Return On Equity of -0.1238. This is 99.48% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 60.06% lower than that of the firm.
RAMM Pharma Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining RAMM Pharma's current stock value. Our valuation model uses many indicators to compare RAMM Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across RAMM Pharma competition to find correlations between indicators driving RAMM Pharma's intrinsic value. More Info.RAMM Pharma Corp is rated below average in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the RAMM Pharma's earnings, one of the primary drivers of an investment's value.RAMM Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RAMM Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of RAMM Pharma could also be used in its relative valuation, which is a method of valuing RAMM Pharma by comparing valuation metrics of similar companies.RAMM Pharma is currently under evaluation in return on equity category among its peers.
RAMM Fundamentals
| Return On Equity | -0.12 | |||
| Return On Asset | -0.0789 | |||
| Profit Margin | (1.76) % | |||
| Operating Margin | (1.89) % | |||
| Current Valuation | 1.85 M | |||
| Shares Outstanding | 122.4 M | |||
| Shares Owned By Insiders | 34.88 % | |||
| Shares Owned By Institutions | 0.89 % | |||
| Price To Book | 0.18 X | |||
| Price To Sales | 4.04 X | |||
| Revenue | 4.12 M | |||
| Gross Profit | (37.32 K) | |||
| EBITDA | (6.36 M) | |||
| Net Income | (7.11 M) | |||
| Cash And Equivalents | 12.79 M | |||
| Cash Per Share | 0.10 X | |||
| Total Debt | 8.69 K | |||
| Current Ratio | 9.18 X | |||
| Book Value Per Share | 0.41 X | |||
| Cash Flow From Operations | (3.82 M) | |||
| Earnings Per Share | (0.05) X | |||
| Beta | -0.75 | |||
| Market Capitalization | 15.16 M | |||
| Total Asset | 59.71 M | |||
| Net Asset | 59.71 M |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in RAMM Pink Sheet
If you are still planning to invest in RAMM Pharma Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RAMM Pharma's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Stocks Directory Find actively traded stocks across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |